US regulators have accepted for review Sanofi/Regeneron’s biologic Dupixent as an add-on maintenance treatment in certain adults and adolescents with moderate-to-severe asthma.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.
Copyright © 2016-2018 Drugdu.com. All Rights Reserved.